Market closedNon-fractional

GlycoMimetics/GLYC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About GlycoMimetics

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Ticker

GLYC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Rockville, United States

Employees

35

GlycoMimetics Metrics

BasicAdvanced
$17M
Market cap
-
P/E ratio
-$0.58
EPS
2.29
Beta
-
Dividend rate
$17M
2.29
6.284
5.929
2.182
-47.82%
-81.84%
1,716.129
0.6
0.6
-0.506
-86.67%
-25.51%
-83.48%
-21.90%

What the Analysts think about GlycoMimetics

Analyst Ratings

Majority rating from 4 analysts.
Buy

GlycoMimetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
18.89%
Profit margin
0.00%
NaN%

GlycoMimetics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.03%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.13
-$0.14
-$0.14
-$0.17
-
Expected
-$0.18
-$0.14
-$0.15
-$0.17
-$0.16
Surprise
-29.09%
-2.33%
-8.20%
3.03%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for GlycoMimetics stock?

GlycoMimetics (GLYC) has a market cap of $17M as of July 06, 2024.

What is the P/E ratio for GlycoMimetics stock?

The price to earnings (P/E) ratio for GlycoMimetics (GLYC) stock is 0 as of July 06, 2024.

Does GlycoMimetics stock pay dividends?

No, GlycoMimetics (GLYC) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next GlycoMimetics dividend payment date?

GlycoMimetics (GLYC) stock does not pay dividends to its shareholders.

What is the beta indicator for GlycoMimetics?

GlycoMimetics (GLYC) has a beta rating of 2.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell GlycoMimetics stock

Buy or sell GlycoMimetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing